Shilajit and Antipsychotics (Olanzapine, Risperidone)
Leila WehrhahnUpdated:Key takeaways:
Shilajit is an ayurvedic resin that contains fulvic acids. There is a lack of reliable data on possible interactions when it is used together with olanzapine or risperidone. Theoretical considerations relate to CYP-mediated pharmacokinetics, hormonal balance and metabolism. Risperidone is often associated with increased prolactin levels. Olanzapine is commonly linked with effects on body weight and blood lipids. Shilajit is sometimes discussed in relation to testosterone and lipid levels. Only products that have been appropriately tested and quality-checked should be used. Medical assessment and ongoing monitoring are advisable.
Shilajit is a naturally occurring resin from the Himalayas containing minerals and fulvic acids, traditionally used within Ayurvedic practices. In recent years, it has been discussed mainly in relation to potential hormonal effects (for example on testosterone) and antioxidant properties. Olanzapine and risperidone are atypical antipsychotics used in conditions such as schizophrenia, bipolar disorder and other indications. At present, there are no robust clinical data on interactions between shilajit and olanzapine/risperidone. Nonetheless, caution is advisable – particularly because of possible effects on hormones and metabolism.
No confirmed interactions, but caution is advised: the hormonal and metabolic effects of shilajit could influence olanzapine/risperidone.
Brief overview of shilajit
Shilajit contains fulvic acids, dibenzo-α-pyrones and trace elements. A small, placebo-controlled study in middle‑aged men reported an increase in total and free testosterone after 90 days (250 mg twice daily). However, these data are limited and cannot readily be extrapolated to people taking antipsychotic medicines (1).
For more on potential mechanisms of action, see our article Shilajit effects.
Mechanism of possible interactions
1) Pharmacokinetics (CYP enzymes)
• Risperidone is mainly metabolised via CYP2D6 to 9‑hydroxyrisperidone (paliperidone); CYP3A4 has a minor role (2).
• Olanzapine is primarily metabolised via CYP1A2 (and UGT1A4); smoking induces CYP1A2 and can thereby lower olanzapine levels (3).
For shilajit itself, there are no reliable human data on inhibition or induction of CYP1A2, CYP2D6 or CYP3A4. Because food supplements can be compositionally complex and some other “health foods” are known to affect P450 enzymes, a theoretical risk of interaction cannot be excluded, although there is no direct evidence for such an effect with shilajit (4).
2) Pharmacodynamics (hormones and prolactin)
Risperidone is often associated with increased prolactin, while olanzapine has this effect less frequently and usually to a milder extent. Raised prolactin levels can be associated with menstrual disturbances, galactorrhoea and sexual dysfunction (5, 6).
Based on smaller studies, shilajit has been reported to influence androgen-related parameters (1). Such an effect could, in theory, subjectively mask or modify prolactin-associated sexual symptoms without addressing the underlying cause (prolactin‑increasing antipsychotics). Robust data on this are lacking.
3) Metabolism
Antipsychotics (particularly olanzapine) are commonly associated with weight gain, dyslipidaemia and insulin resistance. An older human study with shilajit reported improvements in triglycerides/cholesterol and antioxidant markers in healthy volunteers (7). How far this might be relevant for people taking antipsychotics remains unclear.
Shilajit: possible testosterone boost and lipid improvement. Olanzapine/risperidone: prolactin and metabolic effects. No direct interaction data available.

Shilajit Capsules
Clinical evidence
There are currently no controlled studies that have specifically examined shilajit in combination with olanzapine or risperidone. The available evidence is indirect:
- Reported testosterone increase with shilajit in healthy men (1).
- Risperidone exposure is strongly influenced by CYP2D6 status (pharmacogenetics) (2).
- Olanzapine levels and effects are influenced by CYP1A2 (for example, smoking) (3).
- Prolactin increases: marked with risperidone, moderate/low with olanzapine (5, 6).
Conclusion: There are theoretical points of overlap, but robust clinical interaction data are lacking.
Risk assessment
| Active substance | Main metabolism | Hormone/metabolic relevance | Assessment with shilajit |
|---|---|---|---|
| Risperidone | CYP2D6 (± CYP3A4) (2) | Frequently associated with hyperprolactinaemia (5, 6) | Theoretical risk: hormonal “masking”; pharmacokinetic interaction unclear |
| Olanzapine | CYP1A2/UGT (3) | Metabolic burden (weight, lipids, glucose) | Theoretical metabolic conflict (shilajit vs. antipsychotic‑related metabolism); pharmacokinetic interaction unclear |
Additional safety aspects: Ayurvedic products can be contaminated with heavy metals (FDA warning; studies have also reported relevant levels). It is advisable to use only purified, quality‑controlled products (8, 9).
Practical recommendations
- Discuss with a doctor before starting: Clarify diagnosis, current medication (including doses), prolactin/metabolic status and individual aims. Baseline laboratory values may be considered (prolactin, testosterone in men, fasting lipids, fasting glucose/HbA1c, weight/waist circumference).
- Initiation & timing: If a healthcare professional agrees, start with a low dose (for example, 100–200 mg/day of purified shilajit) and increase slowly. Take it 2–3 hours apart from olanzapine/risperidone to reduce potential overlap in pharmacokinetics on a theoretical basis.
- Monitoring (4–12 weeks):
- Symptoms of the underlying condition (no deterioration)
- Prolactin‑associated complaints (cycle changes, libido, galactorrhoea) and laboratory prolactin (particularly important with risperidone) (5, 6).
- Metabolism: weight, waist circumference, lipid profile, glucose/HbA1c.
- Product quality: Use only “purified” shilajit with independent laboratory testing (heavy metals, microbiology) (8).
- Stopping/adjusting: In the event of side effects (gastrointestinal complaints, unusual tiredness, neurological symptoms), increasing prolactin‑related complaints or worsening of psychiatric symptoms, stop shilajit and seek medical advice.
- Alternatives: If prolactin‑related problems are pronounced, the antipsychotic regimen may need to be reassessed (substance‑specific differences) (6) – but only under medical supervision.
For more detailed information, see Shilajit interactions and Shilajit side effects.
🧪 Shilajit Compatibility Check
Find out if there are any known risk factors that could contraindicate taking Shilajit.
Question 1 of 8
Conclusion
There are currently no established clinical data on interactions between shilajit and olanzapine or risperidone. In theory, there are potential points of overlap via hormonal aspects (testosterone vs. prolactin), metabolic effects and the CYP‑dependent pharmacokinetics of these antipsychotics – but without direct evidence specifically for shilajit. Anyone considering shilajit while taking antipsychotics should do so under medical supervision, with careful monitoring and the use of purified, tested products only. Further scientific studies are needed.
Medical disclaimer
Important notice: This information does not replace professional medical advice. Always consult your doctor or pharmacist before taking shilajit together with olanzapine or risperidone. Every individual may respond differently to food supplements and medicines.
